Published 2025-01-01
“…Keri A Streby,1,* Joseph D Tobias,2,3,* Evan McPhaden,4 Shannon Downie,4 Joseph Stanek,1 Catherine Roth,2 Priyal O Patel1,2 1Department of Pediatrics- Division of Pediatric Oncology, Nationwide Children’s Hospital and The Ohio State University College of Medicine, Columbus, OH, USA; 2Department of Anesthesiology & Pain Medicine, Nationwide Children’s Hospital, Columbus, OH, USA; 3Department of Anesthesiology & Pain Medicine, The Ohio State University College of Medicine, Columbus, OH, USA; 4Ohio University Heritage College of
Osteopathic Medicine, Dublin Campus and Ohio University, Athens, OH, USA*These authors contributed equally to this workCorrespondence: Priyal O Patel, DO Department of Anesthesiology & Pain Medicine Nationwide Children’s Hospital, 700 Children’s Drive, Columbus, Ohio, 43205, USA, Tel +1-(614) 722-3728, Fax +1-(614) 722-4203, Email priyal.patel@nationwidechildrens.orgIntroduction: Anti-GD2 immunotherapy has improved outcomes for children with high-risk neuroblastoma (HRNBL). …”
Get full text
Article